MPL Gene Mutation Screening for Myeloproliferative Disease Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for myeloproliferative diseases (MPDs) are inadequate as they fail to effectively identify mutations in patients who are JAK2 V617F negative, limiting accurate diagnosis and patient management.
Innovation Solution
The development of methods to diagnose myeloproliferative diseases by evaluating samples for specific mutations in the MPL gene, including insertion/deletion and point mutations, using nucleic acid and protein analysis techniques.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If diagnostic methods focus only on JAK2 V617F mutation detection, then diagnostic simplicity is maintained, but diagnostic accuracy deteriorates for JAK2 V617F negative patients
Solution Approach 1:
The diagnostic approach is segmented into two distinct parts: first screening for JAK2 V617F mutation, and second screening for MPL mutation only in JAK2 V617F negative patients. This segmentation allows the system to maintain simplicity for the majority of patients while improving accuracy for the specific subgroup that requires additional testing.
Solution Approach 2:
The diagnostic protocol is made dynamic and adaptive based on initial test results. The MPL mutation screening is conditionally applied only to JAK2 V617F negative patients, allowing the diagnostic system to adjust its complexity based on the patient's specific genetic profile rather than applying uniform complex testing to all patients.
2Reliability
If MPL mutation screening is performed on all patients, then diagnostic coverage is improved, but cost and time consumption increase
Solution Approach 1:
The patient population is segmented into two groups based on JAK2 V617F status. MPL mutation screening is applied selectively to the JAK2 V617F negative group, ensuring comprehensive diagnostic coverage for those who need it while avoiding unnecessary testing in JAK2 V617F positive patients, thus reducing overall diagnostic time.
Solution Approach 2:
JAK2 V617F mutation screening is performed as a preliminary test before MPL mutation screening. This preliminary action allows the system to identify which patients require further MPL testing, preventing time waste on patients who already have a positive JAK2 result and do not require additional MPL screening.
3Reliability
If MPL mutation screening is performed on all patients, then diagnostic completeness is improved, but resource consumption increases
Solution Approach 1:
The diagnostic workflow segments patients based on JAK2 V617F status, directing MPL mutation screening resources only to the JAK2 V617F negative population. This segmentation ensures complete diagnostic coverage for the target group while optimizing resource allocation by avoiding redundant testing in JAK2 V617F positive patients.
Solution Approach 2:
Instead of performing MPL mutation screening on all patients (excessive action), the method applies partial screening only to the subset of patients who are JAK2 V617F negative. This partial action is sufficient to achieve diagnostic completeness for the relevant population while reducing overall resource consumption.
Data Source
AI summary
The invention provides compositions and methods for diagnosing a patient as having a myeloproliferative disease by identifying mutations in the MPL gene or gene products.